The promise and practice of cardiovascular risk reduction: A disease management perspective

Canadian Journal of Cardiology

Volumn 12, Issue 10, 1996, Pages 995-999

  Montague, Terrence ^a   Montague, Patricia ^b   Dzavik, Vladimir ^b   Teo, Koon ^b  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b NONE

Author keywords

Cardiovascular risk reduction; Cholesterol; Evidence based therapy

Indexed keywords

CHOLESTEROL; SIMVASTATIN;

AGING; CANADA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEMOGRAPHY; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; REVIEW; RISK; TREATMENT OUTCOME;

CANADA; CHOLESTEROL; CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 0029797519     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Montague T, Taylor L, Barnes M, et al, for the CQIN Investigators. Can practice patterns be successfully altered? Examples from cardiovascular medicine. Can J Cardiol 1995;11:487-92.
2. Montague TJ, Tsuyuki RT, Burton JR, Dzavik V, Williams R, Teo KK. Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy? Chest 1994;105:718-26.
3. Keys A. Seven Countries. A Multivariate Analysis of Health and Coronary Heart Disease. Cambridge: Harvard University Press, 1980.
4. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol and coronary heart disease in population with low cholesterol. BMJ 1991;303:276-82.
5. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne OH, Harlan WR. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992;2:161-6.
6. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995;91:2274-82.
7. The Scandanavtan Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Pitt B, Mancini BJ, Ellis SG, Rosman HS, Park JS, McGovern ME, for the PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-9.
9. Canadian Consensus Conference on Cholesterol: Final Report. The Canadian Consensus Conference on the prevention of heart and vascular disease by altering serum cholesterol and lipoprotein risk factors. Can Med Assoc J 1988;139(Suppl 11):1-8.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
11. The CQIN Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol 1995;76:570-3.
12. Cohen MV, Byrne M, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991;83:1294-304.
13. Northridge DB, Shandall A, Rees A, Buchalter MB. Inadequate management of hyperlipidemia after coronary bypass surgery shown by medical audit. Br Heart J 1994;72:466-7.
14. Neighbor WE, Scott CS, Schaad DC, Macdonald SC, Van Critters R. Assessment and counselling of coronary risk factors by family practice residents. J Fam Pract 1991;32:273-81.
15. Robinson MK, DeHaven MJ, Wallace JB, Fost T. Hypercholesterolemia: case finding in family practice. South Med J 1992;85:1091-5.
16. Rogers LQ, Johnson KC, Arheart KL. Current physician screening and treatment of hypercholesterolemic patients. Am J Med Sci 1993;306:124-8.
17. The HOPE Study Invastigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127-37.
18. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Investigators. Protocol of a trial to evaluate lipid lowering and angiotensin converting enzyme inhibition on coronary atherosclerosis progression and regression in clinically high risk patients with normal cholesterol levels. Medical Research Council and Merck Frosst Inc, Canada, 1991.